Procept BioRobotics Raises $118 Million

Palo Alto – March 19, 2018 – Cooley advised Procept BioRobotics on its $118 million equity financing round led by Viking Global Investors. Partner Mark Weeks led the Cooley team advising Procept.

In addition to Viking Global, the round included participation from new investor Perceptive Advisors and existing investor CPMG. The new funds will support the worldwide commercialization of Procept’s Aquablation therapy for the minimally invasive treatment of benign prostatic hyperplasia (BPH).

“Our investors share our vision to make Aquablation therapy the new standard of care and treatment of choice for BPH,” said Nikolai Aljuri, Procept’s CEO, in a news release. 
Procept’s Aquabeam System is the first FDA-granted surgical robot providing autonomous tissue removal for the treatment of BPH. It is commercially available in the US, Canada, Australia, New Zealand and select European markets.

Based in Silicon Valley, Procept is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology.

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.